Figure 1.
Expression of TETs in patients with ESCC. (A) Overall survival in 12 patients with ESCC in nCRT-well and nCRT-poor group using Kaplan-Meier method for survival analysis by log-rank (Mantel-Cox) test. Expression of (B) TET1, (C) 2 and (D) 3 mRNA in patients with ESCC assessed by unpaired t test. *P<0.05 vs. nCRT-well. (E) Immunohistochemical analysis of paraffin-embedded ESCC tumor tissue labeling TET1, 2 and 3 (magnification, x200). TET, ten-eleven translocation; ESCC, esophageal squamous cell carcinoma; nCRT, neoadjuvant chemoradiotherapy.
